Prognostic Value of Peripheral Blood Lymphocyte Telomere Length in Gynecologic Malignant Tumors
Abstract
:1. Introduction
2. Results
2.1. Relationship between Telomere Length and Clinicopathological Factors
2.2. Effects of Lymphocyte Telomere Length on Progression-Free Survival (PFS)
2.3. Effects of Lymphocyte Telomere Length on Overall Survival (OS)
2.4. Comparison of Lymphocyte Relative Telomere Length before and after Treatment
3. Discussion
4. Materials and Methods
4.1. Patient Data Collection
4.2. Blood Samples
4.3. DNA Extraction for Quantitative PCR
4.4. Measurement of Telomere Length by QRT-PCR
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Grabowski, P.; Hultdin, M.; Karlsson, K.; Tobin, G.; Aleskog, A.; Thunberg, U.; Laurell, A.; Sundström, C.; Rosenquist, R.; Roos, G.; et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation. Blood 2005, 116, 4275–4282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Castro-Duque, A.F.; Loango-Chamorro, N.; Ruiz-Hoyos, B.M.; Landázuri, P. Telomerase activity associated with progression of cervical lesions in a group of Colombian patients. Rev. Bras. Ginecol. Obstet. 2015, 37, 559–564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, X.; Han, W.; Xue, W.; Zou, Y.; Xie, C.; Du, J.; Jin, G. The association between telomere length and cancer risk in population studies. Sci. Rep. 2016, 6, 22243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brazvan, B.; Ebrahimi-Kalan, A.; Velaei, K.; Mehdipour, A.; Aliyari Serej, Z.; Ebrahimi, A.; Ghorbani, M.; Cheraghi, O.; Charoudeh, H.N. Telomerase activity and telomere on stem progeny senescence. Biomed. Pharm. 2018, 102, 9–17. [Google Scholar] [CrossRef] [PubMed]
- Sulin, Z.; Wen, H.; Liu, S.L. Senescence and cancer. Cancer Transl. Med. 2018, 4, 70–74. [Google Scholar]
- Blackburn, E.H.; Greider, C.W.; Szostak, J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med. 2006, 12, 1133–1138. [Google Scholar] [CrossRef]
- Rampazzo, E.; Bertorelle, R.; Serra, L.; Terrin, L.; Candiotto, C.; Pucciarelli, S.; Del Bianco, P.; Nitti, D.; De Rossi, A. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. British J. Cancer 2010, 102, 1300–1305. [Google Scholar] [CrossRef] [Green Version]
- Hahn, W.C. Role of telomeres and telomerase in the pathogenesis of human cancer. J. Clin. Oncol. 2003, 21, 2034–2043. [Google Scholar] [CrossRef] [Green Version]
- Prescott, J.; Wentzensen, I.M.; Savage, S.A.; De Vivo, I. Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat. Res. 2012, 730, 75–84. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Zhao, Q.; Zhu, W.; Liu, T.; Xie, S.H.; Zhong, L.X.; Cai, Y.Y.; Li, X.N.; Liang, M.; Chen, W.; et al. The Association of Telomere Length in Peripheral Blood Cells with Cancer Risk: A Systematic Review and Meta-analysis of Prospective Studies. Cancer Epidemiol. Biomark. Prev. 2017, 26, 1381–1390. [Google Scholar] [CrossRef] [Green Version]
- Wu, X.; Amos, C.I.; Zhu, Y.; Zhao, H.; Grossman, B.H.; Shay, J.W.; Luo, S.; Hong, W.K.; Spitz, M.R. Telomere dysfunction: A potential cancer predisposition factor. J. Natl. Cancer Inst. 2003, 95, 1211–1218. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martinez-Delgado, B.; Yanowsky, K.; Inglada-Perez, L.; Hoya, M.; Caldes, T.; Ana, A.V.; Martin, T.; Rogelio, G.S. Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. J. Med. Genet. 2012, 49, 341–344. [Google Scholar] [CrossRef] [PubMed]
- McGrath, M.; Wong, J.Y.; Michaud, D.; Hunter, D.J.; De Vivo, I. Telomere Length, Cigarette Smoking, and Bladder Cancer Risk in Men and Women. Cancer Epidemiol. Biomark. Prev. 2007, 16, 815–819. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Koh, W.P.; Jin, A.; Wang, R.; Yuan, J.M. Telomere length and risk of developing gastric adenocarcinoma: The Singapore Chinese Health Study. Gastric Cancer 2018, 21, 598–605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qin, Q.; Sun, J.; Yin, J.; Liu, L.; Chen, J.; Zhang, Y.; Li, T.; Shi, Y.; Wei, S.; Nie, S. Telomere length in peripheral blood leukocytes is associated with risk of colorectal cancer in Chinese population. PLoS ONE 2014, 9, e88135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skinner, H.G.; Gangnon, R.E.; Litzelma, K.; Johnson, R.A.; Chari, S.T.; Petersen, G.M.; Boardman, L.A. Telomere Length and Pancreatic Cancer: A Case–Control Study. Cancer Epidemiol. Biomark. Prev. 2012, 21, 2095–3000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, Y.; Zhang, L.; Zhao, L.; Wu, X.; Gu, J. Association of leukocyte telomere length in peripheral blood leukocyte with endometrial cancer risk in Caucasian Americans. Carcinogenesis 2015, 36, 1327–1332. [Google Scholar] [CrossRef]
- Qu, F.; Li, R.; He, X.; Li, Q.; Xie, S.; Gong, L.; Ji, G.; Lu, J.; Bao, G. Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients. Mol. Oncol. 2015, 9, 727–739. [Google Scholar] [CrossRef]
- Chen, Y.; Wu, Y.; Huang, X.; Qu, P.; Li, G.; Jin, T.; Xing, J.; He, S. Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients. J. Cancer Res. Clin. Oncol. 2015, 141, 1739–1747. [Google Scholar] [CrossRef]
- Chen, Y.; Qu, F.; He, X.; Bao, G.; Liu, X.; Wan, S.; Xing, J. Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. Ann. Oncol. 2014, 25, 869–876. [Google Scholar] [CrossRef]
- Bau, D.T.; Lippman, S.M.; Xu, E.; Gong, Y.; Lee, J.J.; Wu, X.; Gu, J. Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer 2013, 11, 4277–4283. [Google Scholar] [CrossRef] [PubMed]
- Svenson, U.; Nordfjäll, K.; Stegmayr, B.; Manjer, J.; Nilsson, P.; Tavelin, B.; Henriksson, R.; Lenner, P.; Roos, G. Breast Cancer Survival Is Associated with Telomere Length in Peripheral Blood Cells. Cancer Res. 2008, 68, 3618–3623. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ojha, J.; Codd, V.; Nelson, C.P.; Samani, N.J.; Smirnov, I.V.; Madsen, N.R.; Hansen, H.M.; De Smith, A.J.; Bracci, P.M.; Wiencke, J.K.; et al. Genetic variation associated with longer telomere length increase risk of chronic lymphocyte leukemia. Cancer Epidemiol. Biomark. Prev. 2016, 25, 1043–1049. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Callahan, C.L.; Schwartz, K.; Ruterbusch, J.J.; Shuch, B.; Graubard, B.I.; Lan, Q.; Cawthon, R.; Baccarelli, A.A.; Chow, W.H.; Rothman, N.; et al. Leukocyte telomere length and renal cell carcinoma survival in two studies. Br. J. Cancer. 2017, 117, 752–755. [Google Scholar] [CrossRef]
- Lin, C.-C.; Chih, H.-F.; Mei, L.; Li, S.; Fe, L.W.; Wen, C. Prognostic factors in epithelial ovarian cancer: A population-based study. PLoS ONE 2018, 13, e0194993. [Google Scholar]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics. Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef] [Green Version]
- Mirabello, L.; Garcia, C.M.; Cawthon, R.; Lissowska, J.; Brinton, L.A.; Pepłońska, B.; Sherman, M.E.; Savage, S.A. Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes Control. 2010, 21, 77–82. [Google Scholar] [CrossRef] [Green Version]
- Yeasmin, S.; Nakayama, K.; Rahman, M.T.; Rahman, M.; Ishikawa, M.; Katagiri, A.; Iida, K.; Nakayama, N.; Otuski, Y.; Kobayashi, H. Biological and clinical significance of NAC1 expression in cervical carcinoma: comparative study. Hum. Pathol. 2012, 43, 506–519. [Google Scholar] [CrossRef]
- Zhang, A.; Wang, J.; Zheng, B.; Fang, X.; Angström, T.; Liu, C.; Li, X.; Erlandsson, F.; Björkholm, M.; Nordenskjörd, M.; et al. Telomere attrition predominantly occours in precursor lesions during in vivi carcinogenic process of the uterine cervix. Oncogene 2004, 23, 7441–7447. [Google Scholar] [CrossRef] [Green Version]
- Yamagami, W.; Nagase, S.; Takahashi, F.; Ino, K.; Hachisuga, T.; Aoki, D.; Katabuchi, H. Clinical statistics of gynecologic cancers in Japan. J. Gynecol. Oncol. 2017, 28, 32. [Google Scholar] [CrossRef] [Green Version]
- Svenson, U.; Grönlund, E.; Söderström, I.; Sitaram, R.T.; Ljungberg, B.; Roos, G. Telomere Length in Relation to Immunological Parameters in Patients with Renal Cell Carcinoma. PLoS ONE 2013, 8, e55543. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Chen, X.; Li, L.; Zhou, Y.; Wang, C.; Hou, S. The Association between Telomere Length and Cancer Prognosis: Evidence from a Meta-Analysis. PLoS ONE 2015, 10, e0133174. [Google Scholar] [CrossRef] [PubMed]
- Meeker, A.K.; Hicks, J.L.; Iacobuzio-Donahue, C.A.; Montgomery, E.A.; Westra, W.H.; Chan, T.Y.; Ronnett, B.M.; De Marzo, A.M. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 2004, 10, 3317–3326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qian, Y.; Ding, T.; Wei, L.; Cao, S.; Yang, L. Shorter telomere length of T-cells in peripheral blood of patients with lung cancer. Onco Targets Ther. 2016, 9, 2675–2682. [Google Scholar] [PubMed] [Green Version]
- Svenson, U.; Roos, G.; Wikström, P. Long leukocyte telomere length in prostate cancer patients at diagnosis is associated with poor metastasis-free and cancer-specific survival. Tumor Biol. 2017, 39, 1010428317692236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ennour-Idrissi, K.; Maunsell, E.; Diorio, C. Telomere Length and Breast Cancer Prognosis: A Systematic Review. Cancer Epidemiol. Biomark. Prev. 2017, 26, 3–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, J.; Maeng, H.G.; Lee, S.J.; Kim, Y.J.; Kim, D.W.; Lee, H.N.; Namgung, J.H.; Oh, H.M.; Kim, T.J.; Jeong, J.E.; et al. Diagnostic value of peripheral blood immune profiling in colorectal cancer. Ann. Surg. Treat. Res. 2018, 94, 312–321. [Google Scholar] [CrossRef] [Green Version]
- Sato, E.; Olson, S.H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Jungbluth, A.A.; Frosina, D.; Gnjatic, S.; Ambrosone, C.; et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 18538–432005. [Google Scholar] [CrossRef] [Green Version]
- Maimela, N.R.; Liu, S.; Zhang, Y. Fates of CD8+ T cells in Tumor Microenvironment. Comput. Struct. Biotechnol. J. 2018, 17, 1–13. [Google Scholar] [CrossRef]
- Di Franco, S.; Turdo, A.; Todaro, M.; Stassi, G. Role of Type i and ii interferons in Colorectal Cancer and Melanoma. Front. Immunol. 2017, 8, 878. [Google Scholar] [CrossRef] [Green Version]
- Milne, K.; Köbel, M.; Kalloger, S.E.; Barnes, R.O.; Gao, D.; Gilks, C.B.; Watson, P.H.; Nelson, B.H. Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS ONE 2009, 4, e6412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arum, C.J.; Anderssen, E.; Viset, T.; Kodama, Y.; Lundgren, S.; Chen, D.; Zhao, C.M. Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer. Neoplasia 2010, 12, 434–442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Holly Kemberling, R.N.; Aleksandra, D.; Eyring, M.P.; Andrew, D.S.; Luber, B.S.S.; Azad, N.S.; et al. PD-1 blockade in tumors with mismatch repair deficiency. N. Engl. J. Med. 2015, 372, 2509–2520. [Google Scholar] [CrossRef] [PubMed]
- Turajlic, S.; Litchfield, K.; Xu, H. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017, 18, 1009–1021. [Google Scholar] [CrossRef] [Green Version]
- Janis, M.; Taube, J.; Anderson, R.A. Colocalization of inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Sci. Transl. Med. 2012, 4, 127ra37. [Google Scholar]
- Teng, M.W.; Ngiow, S.F.; Ribas, A.; Smyth, M.J. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015, 75, 2139–2145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009, 105, 103–104. [Google Scholar] [CrossRef]
- Brandsma, D.; Bent, M.J.V.B. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr. Opin. Neurol. 2009, 22, 633–638. [Google Scholar] [CrossRef]
- Cawthon, R.M. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002, 30, 47. [Google Scholar] [CrossRef]
- Farzaneh-Far, R.; Cawthon, R.M.; Na, B.; Browner, W.S.; Schiller, N.B.; Whooley, M.A. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: data from the Heart and Soul Study. Arte. Thromb. Vasc. Biol. 2008, 28, 1379–1384. [Google Scholar] [CrossRef]
Ovarian Cancer | ||||
Factors | No. of cases (N) | Long RLT | Short RLT | p-Value |
Age (years) | 60.15(14.11) | 69.53(10.71) | 0.002 a | |
Grade | ||||
G1 | 15 | 9(60%) | 6(40%) | 0.69 b |
G2, G3 | 57 | 31(54.38%) | 26(45.61%) | |
FIGO stage | ||||
I, II | 44 | 29(65.90%) | 15(34.09%) | 0.027 b |
III, IV | 28 | 11(39.28%) | 17(60.71%) | |
Histology | ||||
Serous | 35 | 17(48.57%) | 18(51.42%) | 0.49 b |
others | 37 | 15(40.54%) | 22(59.45%) | |
Residual Tumor | ||||
<1cm | 54 | 34(62.96%) | 20(37.03%) | 0.028 b |
≥1cm | 18 | 6(33.33%) | 12(66.66%) | |
Cervical Cancer | ||||
Factors | No. of cases | Long RLT | Short RLT | p-Value |
Age (years) | 48.73(13.93) | 58.35(13.57) | 0.033 a | |
FIGO Stage | ||||
I & IIa | 45 | 30(66.66%) | 15(33.33%) | 0.001 b |
IIb, III, IV | 18 | 4(22.22%) | 14(77.77%) | |
Histology | ||||
SCC | 33 | 16(48.48%) | 17(51.51%) | 0.36 b |
AC/ASC | 30 | 12(40%) | 18(60%) | |
Endometrial Cancer | ||||
Factors | No. of cases | Long RLT | Short RLT | p-Value |
Age (years) | 61.19(13.08) | 59.17(12.85) | 0.021 a | |
Grade | ||||
GI | 47 | 28(59.57%) | 19(40.42%) | 0.17b |
G2, G3 | 40 | 18(45.00%) | 22(55.00%) | |
FIGO Stage | ||||
I, II | 67 | 41(61.19%) | 26(38.80%) | 0.004b |
III, IV | 20 | 5(25%) | 15(75%) | |
Histology | ||||
Endometroid | 72 | 34(47.22%) | 38(52.77%) | 0.96b |
Others | 15 | 7(46.66%) | 8(66.66%) | |
Lymph node metastasis | ||||
Negative | 78 | 45(57.69%) | 33(42.30%) | 0.008b |
Positive | 9 | 1(11.11%) | 8(88.88%) | |
Lymph vascular space | ||||
Negative | 48 | 31(64.58%) | 17(35.41%) | 0.015b |
Positive | 39 | 15(38.46%) | 24(61.53%) | |
Myometrial invasion | ||||
a, b | 65 | 30(46.15%) | 35(53.84%) | 0.75b |
c | 22 | 11(50%) | 11(50%) | |
Menopause | ||||
Pre | 30 | 16(53.33%) | 14(46.66%) | 0.40b |
Post | 57 | 32(56.14%) | 25(43.85%) |
Factors | Patients | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | ||
Age | |||||||
<65 | 33 | 0.98 | 0.45–2.14 | 0.96 | NA | NA | NA |
≥65 | 39 | ||||||
Grade | |||||||
G1 | 15 | 4.39 | 1.04–18.67 | 0.04 | 1.24 | 0.22–6.86 | 0.8 |
G2, G3 | 57 | ||||||
FIGO stage | |||||||
I, II | 44 | 11.57 | 4.53–29.68 | ≤0.001 | 7.97 | 2.36–26.90 | 0.001 |
III, IV | 28 | ||||||
Histology | |||||||
Serous | 35 | 0.47 | 0.21–1.06 | 0.06 | NA | NA | NA |
Others | 37 | ||||||
Residual tumor | |||||||
<1 cm | 54 | 7.34 | 3.20–16.82 | ≤0.001 | 2.09 | 0.78–5.58 | 0.13 |
≥1 cm | 18 | ||||||
RLT | |||||||
Long | 40 | 3.29 | 1.45–7.45 | 0.004 | 2.58 | 1.05–6.34 | 0.03 |
Short | 32 |
Factors | Patients | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | ||
Age | |||||||
<57 | 34 | 1.4 | 0.44–4.68 | 0.56 | NA | NA | NA |
≥57 | 29 | ||||||
FIGO stage | |||||||
I, IIA | 15 | 3.77 | 1.19–11.92 | 0.023 | 1.95 | 0.56–6.78 | 0.28 |
IIB, III, & V | 48 | ||||||
Histology | |||||||
SCC | 33 | 1.09 | 0.35–3.39 | 0.87 | NA | NA | NA |
AC/ASC | 30 | ||||||
RLT | |||||||
long | 34 | 6.88 | 1.80–26.27 | 0.005 | 5.17 | 1.21–22.06 | 0.02 |
Short | 29 |
Factors | Patients | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | ||
Age | |||||||
<65 | 35 | 1.17 | 0.28–4.92 | 0.82 | NA | NA | NA |
≥65 | 37 | ||||||
Grade | |||||||
G1 | 15 | 9.33 | 1.145–76.17 | 0.33 | NA | NA | NA |
G2, G3 | 57 | ||||||
FIGO stage | |||||||
I, II | 44 | 5.96 | 1.19–29.77 | 0.02 | 0.12 | 0.07–2.04 | 0.14 |
III, IV | 28 | ||||||
Histology | |||||||
Serous | 35 | 0.51 | 0.12–2.16 | 0.365 | NA | NA | NA |
Others | 37 | ||||||
Residual tumor | |||||||
<1 cm | 54 | 33.72 | 4.07–279.15 | 0.001 | 124.53 | 5.19–298.53 | 0.003 |
≥1 cm | 18 | ||||||
RLT | |||||||
Long | 40 | 12.44 | 1.15–102.23 | 0.01 | 16.29 | 1.02–259.67 | 0.04 |
Short | 32 |
Factors | Patients | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | ||
Age | |||||||
<57 | 33 | 2.55 | 0.50–12.9 | 0.25 | NA | NA | NA |
≥57 | 39 | ||||||
FIGO stage | |||||||
I, IIA | 15 | 4.73 | 1.13–19.85 | 0.033 | 1.66 | 0.35–7.78 | 0.51 |
IIB, III, & V | 48 | ||||||
Histology | |||||||
SCC | 33 | 1.5 | 0.26–4.21 | 0.94 | NA | NA | NA |
AC/ASC | 30 | ||||||
RLT | |||||||
long | 34 | 14.57 | 1.77–119.84 | 0.01 | 11.26 | 1.17–107.86 | 0.03 |
Short | 29 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shanta, K.; Nakayama, K.; Ishikawa, M.; Ishibashi, T.; Yamashita, H.; Sato, S.; Sasamori, H.; Sawada, K.; Kurose, S.; Mahmud, H.M.; et al. Prognostic Value of Peripheral Blood Lymphocyte Telomere Length in Gynecologic Malignant Tumors. Cancers 2020, 12, 1469. https://doi.org/10.3390/cancers12061469
Shanta K, Nakayama K, Ishikawa M, Ishibashi T, Yamashita H, Sato S, Sasamori H, Sawada K, Kurose S, Mahmud HM, et al. Prognostic Value of Peripheral Blood Lymphocyte Telomere Length in Gynecologic Malignant Tumors. Cancers. 2020; 12(6):1469. https://doi.org/10.3390/cancers12061469
Chicago/Turabian StyleShanta, Kamrunnahar, Kentaro Nakayama, Masako Ishikawa, Tomoka Ishibashi, Hitomi Yamashita, Seiya Sato, Hiroki Sasamori, Kiyoka Sawada, Sonomi Kurose, Hossain Mohammad Mahmud, and et al. 2020. "Prognostic Value of Peripheral Blood Lymphocyte Telomere Length in Gynecologic Malignant Tumors" Cancers 12, no. 6: 1469. https://doi.org/10.3390/cancers12061469